Previous 10 | Next 10 |
Program open at no-cost to any academic researcher interested in submitting a proposal Exscientia (Nasdaq: EXAI) and the University of Oxford Target Discovery Institute (Oxford TDI) today announced the formation of Xcellomics – a program designed to source cel...
AI-driven discovery platform enables new way to find novel pathways as well as progress towards identifying patients who may better respond to drugs in the clinic Preclinical data highlights the potential benefits of Exscientia's AI-driven design to rapidly discover molecules ...
Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO and Ben Taylor, CFO & Chief Strategy Officer, will participate in fireside chats at the following investor conferences in March: Morgan Stanley EMEA HealthTech Conference...
Gainers: IceCure Medical (NASDAQ:ICCM) +16%. Atossa Therapeutics (NASDAQ:ATOS) +15%. G Medical Innovations (NASDAQ:GMVD) +11%. Exscientia (NASDAQ:EXAI) +10%. Immix Biopharma (NASDAQ:IMMX) +10%. Losers: Dermata Therapeutics (NASDAQ:DRMA) -...
Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Exscientia as Chief Scientist of Biologics AI. In this newly created role, she will focus on the application of artificial intelligence (AI), machine learning, and the design of protein structures in the discovery...
Point Roberts, WA and Delta, BC - January 14, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Mining, Plant-Based and Tech. Today's stocks have been added to our lists o...
* Collaborative efforts aim to accelerate drug discovery and improve clinical success * Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection * Research will be focused on up to 15 n...
The healthcare stocks in the S&P 500 with a ~2.5% gain outperformed all other sectors in the broader index thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%. Am...
Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO, Ben Taylor, CFO & Chief Strategy Officer, and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual...
Exscientia plc (EXAI) Q3 2021 Earnings Conference Call November 18, 2021 08:30 ET Company Participants Sara Sherman - Vice President, Investor Relations Andrew Hopkins - Chief Executive Officer Ben Taylor - Chief Financial Officer and Chief Strategy Officer Dave Hallett - Chief Operations Off...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...